Fertility and Reproduction in Male Patients with Ankylosing Spondylitis Treated with Infliximab: Table 1.

Paschou, Sophia; Voulgari, Paraskevi V.; I, Vrabie; Saougou, Ioanna; Drosos, Alexandros A.

doi:10.3899/jrheum.080554

Cited by 64 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, at high tissue concentration, adverse effects on spermatogenesis have also been seen 2. Currently, there are no solid data indicating an impairment of spermatogenesis by TNF antagonists in men 3. A study of three men with SpA treated with infliximab for 8–24 months showed asthenozoospermia (reduced sperm motility) and teratozoospermia (abnormally shaped sperms), but there was no comparison with male patients not treated with TNF inhibitors or with healthy volunteers 4.…”

Section: Introductionmentioning

confidence: 99%

Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis

Villiger

Caliezi²,

Cottin³

et al. 2010

Annals of the Rheumatic Diseases

119

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis

Villiger

Caliezi²,

Cottin³

et al. 2010

Annals of the Rheumatic Diseases

119

View full text Add to dashboard Cite

show abstract

“…The action of the TNF inhibitors on male hormone levels or fertility in general is not known, but the literature suggests an effect, which requires more investigation 9 . TNF-a cytokine inhibitors are associated with vasculitis and a crescentic glomerulonephritis 10 , but not in the absence of ANCA.…”

Section: Rheumatologymentioning

confidence: 99%

Vasculitis, Vitiligo, Thyroiditis, and Altered Hormone Levels After Anti-Tumor Necrosis Factor Therapy

Lahita¹,

Vernace²

2011

J Rheumatol

View full text Add to dashboard Cite

“…Small studies of the effect of infliximab on semen quality in male patients with CD and ankylosing spondylitis have reported a nonsignificant impact of biological agents on semen quality [106,107,108]. Data on indirect exposure to infliximab via the male patient within 3 months of conception were available for 10 patients with CD and rheumatoid arthritis: 9 live births and 1 spontaneous miscarriage (prior to 10 weeks of gestation) were reported.…”

Section: Biological Agents For Fertility the Mother-to-be And Duringmentioning

confidence: 99%

Biological Treatment of Crohn’s Disease

Nielsen

Bjerrum²,

Seidelin³

et al. 2012

Dig Dis

View full text Add to dashboard Cite

Introduction of biological agents for the treatment of Crohn’s disease (CD) has led to a transformation of the treatment paradigm. Several biological compounds have been approved for patients with CD refractory to conventional treatment: infliximab, adalimumab and certolizumab pegol (and natalizumab in several countries outside the European Union). However, despite the use of biologics for more than a decade, questions still remain about the true efficacy and the best treatment regimens – especially about when to discontinue treatment. Furthermore, a need for optimizing treatment with biologics still exists, as 20–40% of patients with CD (depending on selection criteria) do not have any relevant response to the current biological agents (i.e. primary failures). A better patient selection might maximize the clinical outcome while minimizing the complications associated with this type of therapy. However, the clinical tools capable of identifying such patients are still unavailable, and the trough level strategy may help the clinician to optimize therapy and to avoid loss of response and/or immunogenicity (i.e. a low but measurable antibody level exists just before the periodic administration of the biological agent). On the other hand, peak levels and average levels should not exceed concentrations associated with increased toxicity. Randomized, controlled studies focusing on trough levels and antibodies towards the biological agent in routine clinical situations may add important pieces to the puzzle for a more rational treatment algorithm of CD patients. In some situations, the risks (i.e. immunogenicity, serious infections and the promotion of neoplasia) may, however, not outweigh the benefits of biological treatment.

show abstract

Fertility and Reproduction in Male Patients with Ankylosing Spondylitis Treated with Infliximab: Table 1.

Cited by 64 publications

References 28 publications

Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis

Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis

Vasculitis, Vitiligo, Thyroiditis, and Altered Hormone Levels After Anti-Tumor Necrosis Factor Therapy

Biological Treatment of Crohn’s Disease

Contact Info

Product

Resources

About